Top 5 Studies Presented at SABCS 2019

By MD /alert Staff
Save to PDF By

The 2019 San Antonio Breast Cancer Symposium (SABCS) just wrapped up at the Henry B. Gonzalez Convention Center in San Antonio, Texas. Leading researchers presented thousands of studies on the latest advances in breast cancer screening, treatment and management. 

In order to keep you up to speed on the most impactful developments from the 2019 meeting, MD /alert has compiled a list of five studies you shouldn't miss.


Photo by © MedMeetingImages/Todd Buchanan 2019

Oral Paclitaxel Confers Improved Response Rate, Survival Trends in Patients With Metastatic Breast Cancer

Treatment with an oral formulation of the chemotherapy agent paclitaxel resulted in improved response and survival outcomes when compared with the drug in its intravenous (IV) form for women with metastatic breast cancer... READ MORE.

Investigational Monoclonal Antibody Improves PFS in Patients With Pretreated HER2+ MBC

“Margetuximab enhances innate immunity, including CD16A-mediated antibody-dependent cellular cytotoxicity, more effectively than trastuzumab,” according to study presenter Hope S. Rugo, MD, professor of medicine at the University of California… READ MORE.

Palbociclib Combination Therapy Does Not Improve PFS in Women With Progressive Metastatic Breast Cancer

Treatment with the CDK4/6 inhibitor palbociclib, in combination with endocrine therapy, did not significantly improve progression-free survival (PFS) when compared with capecitabine in patients with metastatic breast cancer whose disease progressed on aromatase inhibitor therapy...READ MORE.

Interferon Signaling May Predict CDK4/6 Inhibitor Resistance in ER-Positive, HER2-Negative Breast Cancers

Aberrant interferon signaling may predict acquired resistance to CDK4/6 inhibitors in women with estrogen-receptor positive/HER2-negative and early breast cancers… READ MORE.

Distant Recurrence Risk Decreases Among Recently Diagnosed Women With Node-Negative, ER-Positive Early Breast Cancer

Women diagnosed with node-negative, estrogen receptor-positive early-stage breast cancer in recent years have a lower risk for distant recurrence at 20 years post-diagnosis than those reported at earlier intervals... READ MORE.

 

© 2020 /alert® unless otherwise noted. All rights reserved.
Reproduction in whole or in part without permission is prohibited.
Privacy Policy | Terms of Use
Do Not Sell My Personal Information